Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin

NCT03277183 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

5

Enrollment

FED

Sponsor class

Stopped Lack of enrollment

Conditions

Anemia
CKD
Atherosclerosis
Cardiovascular

Interventions

DRUG: Low dose erythropoietin
DRUG: High dose erythropoietin

Sponsor

VA Office of Research and Development